Metastatic Triple-Negative Breast Cancer (mTNBC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Metastatic Triple-Negative Breast Cancer (mTNBC) Market is segmented By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Novel Drug Candidates), By Route of Administration (Oral, Parenteral, Intravitreal, Subretinal, Topical), By Distribution Channel (Hospitals, Specialty Clinics, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Metastatic Triple-Negative Breast Cancer (mTNBC) Market Size
Market Size in USD
CAGR5%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5% |
| Market Concentration | Medium |
| Major Players | G1 Therapeutics, PharmAbcine/Merck, Roche/Genentech, Bristol Myers Squibb, AstraZeneca |
please let us know !
Metastatic Triple-Negative Breast Cancer (mTNBC) Market Analysis
The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.57 Bn in 2024 and is expected to reach USD 2.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031. The increasing incidence of breast cancer worldwide and limited treatment options for mTNBC are major factors driving the growth of this market.